Proteus mirabilis is a common cause of health care-associated urinary tract infections. Cephalosporins have been used as the drugs of choice to treat infections caused by ampicillin-resistant P. mirabilis. However, P. mirabilis clinical isolates exhibiting resistance to expanded-spectrum -lactam agents have been reported widely in many parts of the world (1-3).Due to the lack of an intrinsic chromosomally encoded -lactamase, cephalosporin resistance in P. mirabilis is entirely dependent upon acquired -lactamases, primarily extended-spectrum -lactamases (ESBLs) and, in some instances, acquired AmpC -lactamases (3-8). The prevalence of ESBL-producing P. mirabilis has increased in several geographical locations; among the ESBLs, the most predominant are CTX-M enzymes, with other -lactamases, such as TEM, VEB, and PER types, being identified at lower frequencies (1).CTX-M-type ESBLs, with 179 variants (as of March 2016), can be grouped into five main clusters according to genetic relatedness (the CTX-M-1, -2, -8, -9, and -25 groups) and into several chimeras, including CTX-M-64, CTX-M-116, CTX-M-123, CTX-M-132, and CTX-M-137. Among them, members of the CTX-M-1 group , the CTX-M-2 group (CTX-M-2), the CTX-M-9 group (CTX-M-9, -14, and -90), and the CTX-M-25 group (CTX-M-25 and -41) have been reported in P. mirabilis (1, 9-11).Here we present data on CTX-M-140, a naturally occurring variant of CTX-M-14 found in P. mirabilis clinical isolates and possessing an amino acid substitution at position 109 (Ala109Thr) and a decreased cephalosporin hydrolytic activity.
MATERIALS AND METHODSPatients, isolates, and plasmids. Four nonduplicate P. mirabilis clinical isolates resistant to third-generation cephalosporins were obtained as part of an antimicrobial resistance monitoring project at a 3,000-bed hospital in Guangdong Province in southern China in July 2012. All four isolates were recovered from urine or other urogenital specimens from inpatients in the urology ward of the hospital. P. mirabilis GB03 was identified from an indwelling catheter urine specimen from an 88-year-old male patient with bladder cancer. P. mirabilis GB08 was cultured from midstream urine of an 80-year-old male patient with bladder cancer. P. mirabilis GB11 was identified from a catheter urine specimen from a 71-year-old